These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Zhang L; Yao Y; Zhang S; Liu Y; Guo H; Ahmed M; Bell T; Zhang H; Han G; Lorence E; Badillo M; Zhou S; Sun Y; Di Francesco ME; Feng N; Haun R; Lan R; Mackintosh SG; Mao X; Song X; Zhang J; Pham LV; Lorenzi PL; Marszalek J; Heffernan T; Draetta G; Jones P; Futreal A; Nomie K; Wang L; Wang M Sci Transl Med; 2019 May; 11(491):. PubMed ID: 31068440 [TBL] [Abstract][Full Text] [Related]
29. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies. Aw A; Brown JR Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906 [TBL] [Abstract][Full Text] [Related]
30. A Novel Aziridine-based Bruton's Tyrosine Kinase Inhibitor Induces Apoptosis Through Down-regulation of p65/RelA Phosphorylation on Serine 536 and ERK1/2 in Mantle Cell Lymphoma. Romanchikova N; Strods A; Strazdina J; Strumfs B; Trapencieris P Anticancer Res; 2016 Nov; 36(11):6133-6140. PubMed ID: 27793942 [TBL] [Abstract][Full Text] [Related]
31. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia. Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M Front Immunol; 2021; 12():766272. PubMed ID: 34912339 [TBL] [Abstract][Full Text] [Related]
32. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells. Ma J; Lu P; Guo A; Cheng S; Zong H; Martin P; Coleman M; Wang YL Br J Haematol; 2014 Sep; 166(6):849-61. PubMed ID: 24957109 [TBL] [Abstract][Full Text] [Related]
33. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma. Guo H; Zeng D; Zhang H; Bell T; Yao J; Liu Y; Huang S; Li CJ; Lorence E; Zhou S; Gong T; Jiang C; Ahmed M; Yao Y; Nomie KJ; Zhang L; Wang M Oncogene; 2019 Mar; 38(11):1802-1814. PubMed ID: 30361685 [TBL] [Abstract][Full Text] [Related]
34. Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines. Restelli V; Lupi M; Vagni M; Chilà R; Bertoni F; Damia G; Carrassa L Target Oncol; 2018 Apr; 13(2):235-245. PubMed ID: 29441438 [TBL] [Abstract][Full Text] [Related]
35. Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma. Zhang XT; Hu XB; Wang HL; Kan WJ; Xu L; Wang ZJ; Xiang YQ; Wu WB; Feng B; Li JN; Gao AH; Dong TC; Xia CM; Zhou YB; Li J Acta Pharmacol Sin; 2021 May; 42(5):814-823. PubMed ID: 32855532 [TBL] [Abstract][Full Text] [Related]
36. XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB. Ming M; Wu W; Xie B; Sukhanova M; Wang W; Kadri S; Sharma S; Lee J; Shacham S; Landesman Y; Maltsev N; Lu P; Wang YL Mol Cancer Ther; 2018 Dec; 17(12):2564-2574. PubMed ID: 30510142 [TBL] [Abstract][Full Text] [Related]
37. Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement. Zinzani PL; Martelli M; Ferrero S; Gentile M; Laurenti L; Romana Mauro F; Sportoletti P; Tedeschi A; Varettoni M; Visco C Hematol Oncol; 2022 Oct; 40(4):518-527. PubMed ID: 35247223 [TBL] [Abstract][Full Text] [Related]
38. Role of Bruton's tyrosine kinase in B cells and malignancies. Pal Singh S; Dammeijer F; Hendriks RW Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639 [TBL] [Abstract][Full Text] [Related]
39. PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR. Jin J; Wang L; Tao Z; Zhang J; Lv F; Cao J; Hu X Mol Med Rep; 2020 May; 21(5):2209-2219. PubMed ID: 32186759 [TBL] [Abstract][Full Text] [Related]
40. The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Yang G; Wang J; Tan L; Munshi M; Liu X; Kofides A; Chen JG; Tsakmaklis N; Demos MG; Guerrera ML; Xu L; Hunter ZR; Che J; Patterson CJ; Meid K; Castillo JJ; Munshi NC; Anderson KC; Cameron M; Buhrlage SJ; Gray NS; Treon SP Blood; 2021 Nov; 138(20):1966-1979. PubMed ID: 34132782 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]